Double maintains 1 strategies that include MLYS - Mineralys Therapeutics, Inc.
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
BTAL | -16.27% | $319.01M | 1.43% |
VIXY | -15.13% | $129.08M | 0.85% |
TAIL | -15.09% | $111.50M | 0.59% |
JMST | -12.79% | $3.78B | 0.18% |
XHLF | -11.61% | $1.48B | 0.03% |
BSMW | -11.36% | $102.19M | 0.18% |
SGOV | -9.83% | $47.19B | 0.09% |
STOT | -9.75% | $234.25M | 0.45% |
FLMI | -8.74% | $684.72M | 0.3% |
XBIL | -8.58% | $782.63M | 0.15% |
CLIP | -8.10% | $1.50B | 0.07% |
MSOS | -8.00% | $332.69M | 0.77% |
FXY | -7.85% | $858.38M | 0.4% |
TBLL | -7.76% | $2.33B | 0.08% |
XONE | -6.90% | $624.08M | 0.03% |
BILS | -6.90% | $3.92B | 0.1356% |
MLN | -6.58% | $528.16M | 0.24% |
IBDQ | -6.51% | $3.06B | 0.1% |
BILZ | -6.05% | $844.17M | 0.14% |
BIL | -5.70% | $43.99B | 0.1356% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
PTGX | 55.11% | $2.94B | +68.63% | 0.00% |
RDFN | 46.58% | $1.28B | +55.12% | 0.00% |
APGE | 34.67% | $2.18B | -19.72% | 0.00% |
ACLX | 34.04% | $3.42B | +19.35% | 0.00% |
CRNX | 33.58% | $2.86B | -31.30% | 0.00% |
OCUL | 32.62% | $1.28B | +40.53% | 0.00% |
EYPT | 32.29% | $498.20M | -32.40% | 0.00% |
KYMR | 31.69% | $1.93B | -7.69% | 0.00% |
KN | 31.53% | $1.43B | -6.34% | 0.00% |
OUST | 31.22% | $657.91M | +4.53% | 0.00% |
KOD | 30.88% | $179.40M | +6.92% | 0.00% |
ORA | 30.68% | $4.51B | -1.42% | 0.65% |
CELC | 30.52% | $402.52M | -32.72% | 0.00% |
XNCR | 30.36% | $569.37M | -66.33% | 0.00% |
ALB | 30.11% | $6.56B | -54.52% | 2.88% |
KRYS | 30.03% | $3.64B | -21.30% | 0.00% |
FBIO | 29.85% | $55.89M | +2.72% | 0.00% |
IGMS | 29.77% | $76.35M | -84.75% | 0.00% |
IMVT | 29.59% | $2.52B | -41.51% | 0.00% |
ALKS | 29.47% | $5.05B | +30.81% | 0.00% |
Yahoo
Mineralys Therapeutics (MLYS) announced detailed results from the pivotal Phase 3 Launch-HTN trial in over 1,000 participants with uncontrolled hypertension or resistant hypertension who were taking two to five antihypertensive medications. Results from Launch-HTN were presented in a late-breaking session at the 34th European Meeting on Hypertension and Cardiovascular Protection on Saturday, May 24. When added to existing background treatment, lorundrostat 50 mg dosed once daily demonstrated cli
Yahoo
Lorundrostat dosed at 50mg once a day minimised automatised office systolic blood pressure.
Finnhub
RADNOR - Mineralys Therapeutics, Inc. , a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease , obstructive sleep apnea and other...
Yahoo
– Largest hypertension trial of an aldosterone synthase inhibitor to date demonstrated the efficacy of lorundrostat in over 1,000 participants with uncontrolled or resistant hypertension in a real-world setting – – Lorundrostat 50 mg dosed once daily demonstrated clinically meaningful and sustained reductions in systolic blood pressure, with a 16.9 mmHg reduction at Week 6 (-9.1 mmHg placebo adjusted) and a 19.0 mmHg reduction at Week 12 (-11.7mm placebo adjusted) – – Lorundrostat demonstrated a
Finnhub
Mineralys Therapeutics Inc: * MINERALYS THERAPEUTICS INC - LORUNDROSTAT SHOWS 16.9 MMHGREDUCTION AT WEEK 6, 19.0 MMHG AT WEEK 12 * MINERALYS THERAPEUTICS INC -...
Yahoo
Mineralys Therapeutics, Inc. (MLYS) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
TEO | 0.01% | $1.22B | +11.30% | 0.00% |
HUM | 0.01% | $28.14B | -34.90% | 1.53% |
PARAA | 0.04% | $15.27B | +9.58% | 0.88% |
ARLO | 0.05% | $1.48B | +0.77% | 0.00% |
CODI | -0.08% | $505.59M | -70.47% | 14.90% |
PEP | 0.09% | $180.23B | -23.97% | 4.15% |
OHI | 0.09% | $10.71B | +14.44% | 7.27% |
EZPW | 0.09% | $739.94M | +28.22% | 0.00% |
KNTK | 0.10% | $2.71B | +8.66% | 6.80% |
FYBR | 0.10% | $9.07B | +35.90% | 0.00% |
CEG | -0.12% | $95.95B | +40.92% | 0.48% |
ALLT | 0.13% | $342.15M | +302.80% | 0.00% |
GSHD | -0.13% | $2.71B | +77.34% | 0.00% |
FARM | -0.14% | $32.98M | -46.88% | 0.00% |
UNH | 0.15% | $273.87B | -39.05% | 2.76% |
RACE | 0.16% | $85.32B | +16.49% | 0.71% |
NI | 0.18% | $18.61B | +36.06% | 2.77% |
CREG | 0.20% | $16.71M | -23.00% | 0.00% |
AEM | 0.22% | $59.65B | +72.98% | 1.66% |
EBAY | -0.22% | $33.72B | +34.95% | 1.90% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
RKT | -19.13% | $1.93B | -3.07% | 0.00% |
K | -18.29% | $28.67B | +36.94% | 2.76% |
STG | -14.97% | $29.12M | -21.90% | 0.00% |
PULM | -13.85% | $32.80M | +380.21% | 0.00% |
VHC | -13.00% | $32.89M | +88.35% | 0.00% |
COKE | -12.99% | $8.96B | +16.87% | 7.05% |
FAT | -11.69% | $39.03M | -33.26% | 12.43% |
BTCT | -11.47% | $21.49M | +46.48% | 0.00% |
CLX | -11.11% | $16.25B | +0.24% | 3.72% |
LFVN | -7.65% | $164.28M | +71.48% | 1.57% |
NPWR | -7.57% | $165.56M | -79.73% | 0.00% |
WELL | -7.32% | $100.89B | +48.82% | 1.74% |
FLUT | -7.25% | $44.65B | +31.55% | 0.00% |
CL | -6.81% | $75.32B | -0.02% | 2.18% |
RDDT | -5.90% | $20.73B | +107.14% | 0.00% |
FRPT | -5.84% | $3.91B | -38.89% | 0.00% |
PRPH | -5.57% | $15.35M | -92.83% | 0.00% |
CRMD | -5.56% | $823.39M | +130.36% | 0.00% |
VSCO | -5.55% | $1.69B | -6.93% | 0.00% |
KDP | -5.55% | $45.73B | -1.69% | 2.71% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
USDU | -0.07% | $169.08M | 0.5% |
SOYB | -0.12% | $25.65M | 0.22% |
SPTS | 0.17% | $5.74B | 0.03% |
IBMS | -0.19% | $74.91M | 0.18% |
LMBS | 0.22% | $5.00B | 0.64% |
SHM | 0.23% | $3.39B | 0.2% |
CGMU | 0.27% | $3.22B | 0.27% |
BSCP | -0.28% | $3.40B | 0.1% |
IBTG | -0.42% | $1.91B | 0.07% |
TAXF | 0.43% | $495.14M | 0.29% |
MUST | 0.47% | $423.94M | 0.23% |
IBTK | 0.48% | $446.12M | 0.07% |
VGSH | -0.50% | $22.46B | 0.03% |
DFNM | 0.56% | $1.55B | 0.17% |
TPMN | -0.59% | $30.91M | 0.65% |
HYMB | 0.63% | $2.52B | 0.35% |
AGZD | 0.64% | $106.90M | 0.23% |
ITM | 0.68% | $1.89B | 0.18% |
TFLO | -0.71% | $7.00B | 0.15% |
MMIN | -0.75% | $485.89M | 0.3% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
XBI | 37.43% | $4.74B | 0.35% |
PBE | 36.62% | $224.00M | 0.58% |
IBB | 34.58% | $5.22B | 0.45% |
XPH | 32.73% | $140.33M | 0.35% |
ARKG | 32.44% | $869.55M | 0.75% |
GNOM | 31.40% | $41.28M | 0.5% |
BBH | 30.07% | $333.83M | 0.35% |
FBT | 30.05% | $1.04B | 0.54% |
IWC | 29.22% | $780.77M | 0.6% |
PTH | 28.97% | $98.10M | 0.6% |
PINK | 28.68% | $131.52M | 0.5% |
IWO | 28.49% | $11.10B | 0.24% |
IWM | 27.35% | $62.35B | 0.19% |
CALF | 27.35% | $4.31B | 0.59% |
VTWO | 27.06% | $11.96B | 0.07% |
PBW | 26.63% | $296.96M | 0.65% |
KJAN | 26.21% | $297.22M | 0.79% |
COWZ | 26.07% | $21.06B | 0.49% |
GSSC | 25.88% | $529.45M | 0.2% |
DRIV | 25.88% | $299.67M | 0.68% |
Current Value
$15.741 Year Return
Current Value
$15.741 Year Return